Back to top
more

Inogen (INGN)

(Delayed Data from NSDQ)

$6.21 USD

6.21
444,994

-0.10 (-1.58%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $6.23 +0.02 (0.32%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (159 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Add Inogen Stock to Your Portfolio Now

by Zacks Equity Research

Expanding product portfolio and high prospects for POC raise optimism for INGN stock.

Zacks Equity Research

Inogen (INGN) Down 0.8% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Here's Why You Should Add Inogen Stock to Your Portfolio Now

by Zacks Equity Research

Expanding product portfolio and high prospects for POC raise optimism for INGN stock.

Zacks Equity Research

Zacks.com featured highlights Urban Outfitters, Inogen and Southwest Gas

by Zacks Equity Research

Urban Outfitters, Inogen and Southwest Gas see rising broker confidence with earnings growth forecasts and notable rating upgrades.

Swayta Shah headshot

3 Stocks With Upgraded Broker Ratings to Bet on Amid Uncertainties

by Swayta Shah

Broker upgrades boost URBN, INGN and SWX, with earnings growth and strong Zacks Ranks signaling potential upside despite market volatility.

Zacks Equity Research

What Makes Inogen (INGN) a New Buy Stock

by Zacks Equity Research

Inogen (INGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

After Plunging -15.69% in 4 Weeks, Here's Why the Trend Might Reverse for Inogen (INGN)

by Zacks Equity Research

Inogen (INGN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Equity Research

INGN Stock Gains Following Q1 Earnings Beat, Revenues Up Y/Y

by Zacks Equity Research

Inogen's overall first-quarter 2025 results continue to gain from higher business-to-business sales.

Zacks Equity Research

Here's What Key Metrics Tell Us About Inogen (INGN) Q1 Earnings

by Zacks Equity Research

Although the revenue and EPS for Inogen (INGN) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Inogen (INGN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Inogen (INGN) delivered earnings and revenue surprises of 51.92% and 3.26%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Harshit Gupta headshot

MedTech Stocks' Earnings to Watch on May 7: COR, QDEL & INGN

by Harshit Gupta

The medical device industry is growing fast in 2025, but faces supply and trade issues. Major companies are set to report earnings on May 7, stay tuned!

Zacks Equity Research

Mettler-Toledo (MTD) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Mettler-Toledo (MTD) delivered earnings and revenue surprises of 3.67% and 1%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why You Should Retain Inogen Stock in Your Portfolio Now

by Zacks Equity Research

Expanding product portfolio and high prospects for POC raise optimism for INGN stock.

Zacks Equity Research

Inogen (INGN) Down 11.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Inogen (INGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for Inogen (INGN) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Here's Why You Should Retain Inogen Stock in Your Portfolio Now

by Zacks Equity Research

Expanding product portfolio and high prospects for POC raise optimism for INGN stock

Zacks Equity Research

INGN Stock Gains Following Q4 Earnings Beat, Adjusted Gross Margin Up

by Zacks Equity Research

Inogen's overall fourth-quarter 2024 results continue to gain from higher business-to-business sales.

Zacks Equity Research

Inogen (INGN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Inogen (INGN) delivered earnings and revenue surprises of 28.07% and 0.73%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

The Zacks Analyst Blog Highlights Fresenius Medical, Masimo, Merit Medical Systems and Inogen

by Zacks Equity Research

Fresenius Medical, Masimo, Merit Medical Systems and Inogen are included in this Analyst Blog.

Indrajit Bandyopadhyay headshot

What to Expect From These 4 Medical Device Stocks in Q4 Earnings?

by Indrajit Bandyopadhyay

Here is a sneak peek into how four Medical Device stocks, namely FMS, MASI, MMSI and INGN, are expected to fare in their quarterly results, slated to be released tomorrow.

Zacks Equity Research

Here's Why You Should Add Inogen Stock to Your Portfolio Now

by Zacks Equity Research

Expanding product portfolio and high prospects for POC raise optimism for INGN stock.

Zacks Equity Research

COR Stock Gains on Q1 Earnings & Revenue Beat & Upbeat '25 Outlook

by Zacks Equity Research

COR's first-quarter fiscal 2025 results showcase a strong segmental performance. The company's sales and earnings guidance for fiscal 2025 looks encouraging.

Zacks Equity Research

Reasons to Retain Inari Medical Stock in Your Portfolio for Now

by Zacks Equity Research

NARI continues to gain from its expanded product portfolio. The company's expansion in China and Japan bodes well.

Zacks Equity Research

RVTY Q4 Earnings Beat Estimates, Sales Miss, Segments Robust

by Zacks Equity Research

Revvity's fourth-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales.

Zacks Equity Research

Inogen Stock May Gain on Deal With Yuwell to Expand Global Reach

by Zacks Equity Research

INGN and Yuwell collaborate to expand and enhance Inogen's innovation pipeline through R&D collaboration and accelerate the entry of Inogen's brand into the Chinese market.